The testing specialist organization SCL (Seoul Clinical Laboratories Foundation) announced on the 20th that it is pursuing the advancement of its digital pathology system and preparing to introduce an artificial intelligence (AI)-based analysis solution. The move is aimed at enhancing diagnostic accuracy and efficiency.

As medical technology advances, digital transformation is rapidly progressing in the field of pathology diagnostics as well. Based on its already established digital pathology infrastructure, SCL has embarked on system upgrades. The company plans to improve both the accuracy of the interpretation process and work efficiency through this initiative.

● Digital pathology combined with AI…market continues to expand

A digital pathology system converts pathology slides into digital images for analysis, and its range of applications has been expanding recently as it is combined with AI technology. AI-based image analysis is used to complement the limitations of conventional methods in lesion detection, classification, and quantification processes.

With cloud-based data storage and sharing technologies also spreading, digital pathology is being utilized across various areas including remote diagnosis, collaborative consultations, and education.

According to market research firm Mordor Intelligence, the global digital pathology market size is projected to grow at a compound annual rate of 18.63% from approximately USD 1.58 billion in 2023 to about USD 3.71 billion in 2028.

● System introduced in 2023…expanding the foundation for data utilization

SCL introduced a digital pathology system in 2023, the first among domestic testing institutions to do so. The company explained that this has improved accessibility to pathology data and enhanced efficiency in the interpretation process.

The pathology data accumulated after the digital transition is forming a foundation for future AI analysis and research utilization. SCL is currently operating a digital collaborative consultation system and an online slide review service.

SCL is pushing to introduce an AI-based immunohistochemistry (IHC) analysis algorithm in the second half of this year. The system analyzes whole slide images (WSI) to detect positive cells and visualize their distribution.

The company expects this to improve diagnostic accuracy and shorten interpretation time.

Kwon Gwi-young, Head of the Department of Pathology at SCL, said, “Digital pathology data have potential for use in future new drug development and disease research.”

Popular News